Astragaloside <scp>IV</scp> and Ferroptosis Modulation in Pathological Cardiac Hypertrophy: Current Evidence, an Integrative Hypothesis, and Future Directions

Pengbo Liu, Yongzhi Deng

Open source

DOI
10.1002/prp2.70334
Published
2026-10-16
Container
Pharmacology Research &amp; Perspectives
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/prp2.70334,
  title = {Astragaloside
                    <scp>IV</scp>
                    and Ferroptosis Modulation in Pathological Cardiac Hypertrophy: Current Evidence, an Integrative Hypothesis, and Future Directions},
  author = {Pengbo Liu and Yongzhi Deng},
  year = {2026},
  journal = {Pharmacology Research \&amp; Perspectives},
  doi = {10.1002/prp2.70334},
  url = {https://doi.org/10.1002/prp2.70334}
}

RIS

TY  - JOUR
TI  - Astragaloside
                    <scp>IV</scp>
                    and Ferroptosis Modulation in Pathological Cardiac Hypertrophy: Current Evidence, an Integrative Hypothesis, and Future Directions
AU  - Pengbo Liu
AU  - Yongzhi Deng
PY  - 2026
JO  - Pharmacology Research &amp; Perspectives
DO  - 10.1002/prp2.70334
UR  - https://doi.org/10.1002/prp2.70334
ER  - 

APA

Liu, P., & Deng, Y. (2026). Astragaloside <scp>IV</scp> and Ferroptosis Modulation in Pathological Cardiac Hypertrophy: Current Evidence, an Integrative Hypothesis, and Future Directions. Pharmacology Research &amp; Perspectives. https://doi.org/10.1002/prp2.70334

Source records